Novartis International Pharmaceutical, Ltd.

Smithkline Beecham Corporation

Beecham Group Plc

Beecham Plc

David Sutton

Malcolm Richard Boyd

Richard Anthony Vere Hodge

Martin Cole

The use of a compound of formula (A) or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing for use in the prophylactic treatment of HHV-6 infection.

Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections

A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or penciclorivir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.

Nucleoside analogs in combination therapy of herpes simplex infections

Pharmaceutical use of a compound of formula (A): ##STR1## or a pro-drug, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing; in the treatment of hepatitis B virus infections.

Pharmaceutical treatment

The use of a compound of formula (A) or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing in the manufacture of a medicament for use in the treatment (including prophylaxis) of HHV-6 infection. ##STR1##

Use of 2-amino purine derivatives for the treatment and prophylaxis of

Pharmaceutical product comprising an interferon and a compound of formula (A) ##STR1## or a pro-drug, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative or either of the foregoing as a combined preparation for simultaneous, separate or sequential use in antiviral therapy.

Growing community of inventors

Epsom, United Kingdom

Malcolm Richard Boyd